ClinicalTrials.gg
CompletedNCT00113165Updated Dec 5, 2016

Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures

A Phase 3 interventional study of LAMICTAL extended-release in Epilepsy and Epilepsy, Partial, sponsored by GlaxoSmithKline. Completed at 148 sites in 10 countries. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2016-12-05.

Primary conditionEpilepsies, PartialRegistry: EpilepsyReclassifiedWhy we changed it
Registry
Epilepsy — the first condition term the registry derived for this study.
ClinicalTrials.gg
Epilepsies, Partial
Why
  1. The study's listed conditions name Epilepsies, Partial, a narrower term within Epilepsy.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
244
Allocation
Randomized
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 102 studies in Epilepsies, Partial with a site in United States — 18 open to participants now, 24 under way, 6 of them phase 3. Epilepsies, Partial · United States.

Enrollment
24th of 86
244 · median 100
Started
2004
with 5 others
Phase 3
31 of 102
3 open now
Registered
10th of 102
by date

Among the 102 studies in Epilepsies, Partial with a site in United States, this one is the 24th largest by enrollment of the 86 interventional ones that give a count, is one of 6 that started in 2004, is one of 31 in phase 3, and was the 10th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

18 of the 102 studies in Epilepsies, Partial with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Epilepsies, Partial with a site in United States, or all of them as a file.
02

Study summary

This study is being conducted to compare the efficacy and safety of LAMICTAL (lamotrigine) extended-release with placebo in the treatment of partial seizures. LAMICTAL extended-release is an investigational drug. Placebo tablets look like LAMICTAL extended-release tablets but do not contain active medication. In this study, LAMICTAL extended-release or placebo tablets will be added to current seizure treatments.

03

Conditions studied

  • Epilepsy
  • Epilepsy, Partial

Browse trials for

Keywords

  • partial seizures
  • Epilepsy
  • antiepileptic drugs
  • anticonvulsants
  • LAMICTAL
  • seizures
  • lamotrigine
04

In context

Epilepsies, Partial Reclassified

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

This study's enrollment of 244 is above the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.

Browse Epilepsies, Partial studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Epilepsies, Partial, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsy. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of epilepsy with partial seizures for more than 24 weeks.
  • Must experience at least 8 partial seizures during an 8-week Baseline Phase.
  • Must currently be receiving treatment with a stable regimen of one or two antiepileptic drugs for at least four weeks.
  • Patient or parent/caregiver must be willing and able to maintain a written daily seizure diary.

Exclusion criteria

Exclusion criteria:

  • Previous treatment with lamotrigine.
  • Exhibits any primary generalized seizures.
  • Receiving treatment with felbamate or currently following the ketogenic diet.
  • Pregnant, breastfeeding, or planning to become pregnant.
06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
244 participants (actual)

Interventions

07

What researchers measure

Primary outcomes

  1. The efficacy of LAMICTAL extended-release therapy will be measured by the percentage change from Baseline in partial seizure frequency during the double-blind treatment phase.

    Time frame: 24 Weeks

Secondary outcomes

  1. Reduction in partial seizure frequency during portions of double-blind phase (=25%,=50%,=75%,100%). Time to 50% reduction in partial seizure frequency. Adverse events. Weight change. Health outcomes questionnaires. Population Pharmacokinetics

    Time frame: 24 Weeks

08

Study locations

148 sites
  • GSK Investigational Site
    Anniston, Alabama 36207, United States
  • GSK Investigational Site
    Birmingham, Alabama 35294-0021, United States
  • GSK Investigational Site
    Northport, Alabama 35476, United States
  • GSK Investigational Site
    Tuscaloosa, Alabama 35406, United States
  • GSK Investigational Site
    Mesa, Arizona 85201, United States
  • GSK Investigational Site
    Phoenix, Arizona 85006, United States
  • GSK Investigational Site
    Scottsdale, Arizona 85259, United States
  • GSK Investigational Site
    Sun City, Arizona 85351, United States
  • GSK Investigational Site
    Tucson, Arizona 85712, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72205, United States
  • GSK Investigational Site
    Los Angeles, California 90033, United States
  • GSK Investigational Site
    Los Angeles, California 90073, United States
  • GSK Investigational Site
    Newport Beach, California 92660, United States
  • GSK Investigational Site
    Santa Monica, California 90404, United States
  • GSK Investigational Site
    Sepuldeva, California 91343, United States
  • GSK Investigational Site
    Washington, District of Columbia 20016, United States
  • GSK Investigational Site
    Washington, District of Columbia 20037, United States
  • GSK Investigational Site
    Hollywood, Florida 33021, United States
  • GSK Investigational Site
    Maitland, Florida 32751, United States
  • GSK Investigational Site
    Ocala, Florida 34471, United States
  • GSK Investigational Site
    Tallahassee, Florida 32308, United States
  • GSK Investigational Site
    Tampa, Florida 33609, United States
  • GSK Investigational Site
    Atlanta, Georgia 30342, United States
  • GSK Investigational Site
    Augusta, Georgia 30912, United States
  • GSK Investigational Site
    Austell, Georgia 30106, United States
  • GSK Investigational Site
    Savannah, Georgia 31405, United States
  • GSK Investigational Site
    Chicago, Illinois 60612, United States
  • GSK Investigational Site
    Flossmoor, Illinois 60422, United States
  • GSK Investigational Site
    Springfield, Illinois 62702, United States
  • GSK Investigational Site
    Des Moines, Iowa 50309-1426, United States
  • GSK Investigational Site
    Wichita, Kansas 67214, United States
  • GSK Investigational Site
    Crestview Hills, Kentucky 41017, United States
  • GSK Investigational Site
    Lexington, Kentucky 40536-0284, United States
  • GSK Investigational Site
    Louisville, Kentucky 40202, United States
  • GSK Investigational Site
    Boston, Massachusetts 02118, United States
  • GSK Investigational Site
    Boston, Massachusetts 02215, United States
  • GSK Investigational Site
    Detroit, Michigan 48202, United States
  • GSK Investigational Site
    Grand Rapids, Michigan 49525, United States
  • GSK Investigational Site
    Traverse City, Michigan 49684, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55422, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55454, United States
  • GSK Investigational Site
    Chesterfield, Missouri 63017, United States
  • GSK Investigational Site
    Kansas City, Missouri 64111, United States
  • GSK Investigational Site
    St. Louis, Missouri 63110, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89103, United States
  • GSK Investigational Site
    Edison, New Jersey 08818, United States
  • GSK Investigational Site
    West Orange, New Jersey 07052, United States
  • GSK Investigational Site
    New York, New York 10016, United States
  • GSK Investigational Site
    Plainview, New York 11803, United States
  • GSK Investigational Site
    Asheville, North Carolina 28801, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27514, United States
  • GSK Investigational Site
    Greenville, North Carolina 27834, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27607, United States
  • GSK Investigational Site
    Columbus, Ohio 43210-1250, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73112, United States
  • GSK Investigational Site
    Cheswick, Pennsylvania 15024, United States
  • GSK Investigational Site
    Greensburg, Pennsylvania 15601, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • GSK Investigational Site
    Dallas, Texas 75230, United States
  • GSK Investigational Site
    Dallas, Texas 75235, United States
  • GSK Investigational Site
    Galveston, Texas 77555, United States
  • GSK Investigational Site
    Houston, Texas 77005, United States
  • GSK Investigational Site
    San Antonio, Texas 78258, United States
  • GSK Investigational Site
    Wichita Falls, Texas 76301, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84107, United States
  • GSK Investigational Site
    Richmond, Virginia 23220, United States
  • GSK Investigational Site
    Seattle, Washington 98122-4358, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53215, United States
  • GSK Investigational Site
    Capital Federal, Buenos Aires 1181, Argentina
  • GSK Investigational Site
    Curitiba, Paraná 80069-900, Brazil
  • GSK Investigational Site
    Campinas, São Paulo 13083-970, Brazil
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 7571831, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago, Chile
  • GSK Investigational Site
    Singen, Baden-Wuerttemberg 78224, Germany
  • GSK Investigational Site
    Ulm, Baden-Wuerttemberg 89073, Germany
  • GSK Investigational Site
    Alzenau, Bayern 63755, Germany
  • GSK Investigational Site
    Bamberg, Bayern 96047, Germany
  • GSK Investigational Site
    Fuerth, Bayern 90762, Germany
  • GSK Investigational Site
    Muenchen, Bayern 80331, Germany
  • GSK Investigational Site
    Neuoetting, Bayern 84524, Germany
  • GSK Investigational Site
    Straubing, Bayern 94315, Germany
  • GSK Investigational Site
    Unterhaching, Bayern 82008, Germany
  • GSK Investigational Site
    Wuerzburg, Bayern 97070, Germany
  • GSK Investigational Site
    Bernau, Brandenburg 16321, Germany
  • GSK Investigational Site
    Ludwigsfelde, Brandenburg 14974, Germany
  • GSK Investigational Site
    Bad Homburg, Hessen 61348, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60594, Germany
  • GSK Investigational Site
    Giessen, Hessen 35390, Germany
  • GSK Investigational Site
    Wismar, Mecklenburg-Vorpommern 23966, Germany
  • GSK Investigational Site
    Wismar, Mecklenburg-Vorpommern 23970, Germany
  • GSK Investigational Site
    Bueckeburg, Niedersachsen 31675, Germany
  • GSK Investigational Site
    Goettingen, Niedersachsen 37075, Germany
  • GSK Investigational Site
    Osnabrueck, Niedersachsen 49074, Germany
  • GSK Investigational Site
    Baesweiler, Nordrhein-Westfalen 52499, Germany
  • GSK Investigational Site
    Bochum, Nordrhein-Westfalen 44795, Germany
  • GSK Investigational Site
    Bochum, Nordrhein-Westfalen 44892, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45122, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45138, Germany

Showing the first 100 of 148 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Naritoku DK, Warnock CR, Messenheimer JA, Borgohain R, Evers S, Guekht AB, Karlov VA, Lee BI, Pohl LR. Lamotrigine extended-release as adjunctive therapy for partial seizures. Neurology. 2007 Oct 16;69(16):1610-8. doi: 10.1212/01.wnl.0000277698.33743.8b. Erratum In: Neurology. 2009 Jan 13;72(2):201. PubMed 17938371 ↗
  • van Dijkman SC, de Jager NCB, Rauwe WM, Danhof M, Della Pasqua O. Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials. Clin Pharmacokinet. 2018 Aug;57(8):1039-1053. doi: 10.1007/s40262-017-0614-5. Erratum In: Clin Pharmacokinet. 2018 Aug;57(8):1055-1056. doi: 10.1007/s40262-018-0660-7. PubMed 29363050 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2004, a primary completion of Jul 2007 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2005
First posted
Jun 7, 2005
Start
Oct 2004
Primary completionActual
Jul 2007
CompletionActual
Jul 2007
Last update
Dec 5, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00113165
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 7, 2005
Start date
Oct 2004
Primary completion
Jul 2007
Completion
Jul 2007
Last update
Dec 5, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamotrigine

Start the discussion